Emet Surgical Accepted into Innosphere Ventures Life Sciences Incubator Program
Emet Surgical, developers of innovative tools to improve surgery outcomes, today announced its acceptance into the Innosphere Ventures Life Sciences Incubator for pioneering startups, a program of impact nonprofit Innosphere Ventures.
Innosphere's incubation programs support the commercialization efforts of entrepreneurs, technical founders and university researchers who are launching and scaling high-tech startups. The Innosphere Ventures Regional Life Sciences Incubator accelerates the success of founders building technology and science-based companies through its incubation programs, office and specialized wet laboratory facilities, and venture capital funds.
"Emet Surgical's innovative approach to improving surgery outcomes, born out of firsthand experience and a commitment to addressing critical challenges in the field, exemplifies the spirit of entrepreneurship and innovation that defines our cohort," said Kevin Noble, Life Sciences Program Director for Innosphere. "We look forward to supporting Emet Surgical as they continue to develop groundbreaking solutions that have the potential to make a significant impact on patient care and surgical practices."
"We thank Innosphere for this opportunity to access their resources, network, and facilities as we move from an R&D company to the commercialization stage," said Bob Witkow, founder and CEO of Emet Surgical. "With the support of this program we expect to be able to set the stage for market readiness, attract investors and stakeholders, and expand our team intelligently."
Innosphere is a non-profit 501(c)(3) organization with a mission to create jobs and grow the Colorado region's entrepreneurship ecosystem. Innosphere has been supporting startups for 26 years by creating long-term, regional economic impact by offering its clients access to a broad network of specialized resources.
Emet Surgical's TrueMargintm, currently awaiting U.S. FDA 510(k) clearance, is an easy-to-use tumor margin-marking system that requires no new tools and no new training for surgeons, and can be simply added to surgical and pathology workflows. TrueMargin provides specific in-vivo and ex-vivo location and orientation details, unlike conventional tumor marking that is often incomplete and results in the need for follow-up surgeries. Healthcare organizations and teams can achieve measurable productivity improvements and cost savings with TrueMargin.
Emet Surgical has opened a StartEngine share offering that will help the company reach its goal of enhancing cancer patient surgery outcomes while providing improved ROI for healthcare providers and insurers. Participants in the StartEngine campaign will be among the first investors of a pioneering medical technology company that is part of an estimated $536.12 billion global medical device market. Those interested in reserving a spot in the StartEngine funding round can visit https://www.startengine.com/offering/emetsurgical
About Emet Surgical
Taking its name from the Hebrew word for "truth," Emet Surgical is enabling true surgeon/pathologist collaboration. Emet Surgical's TrueMargintm tumor margin marking tools, now under regulatory review, provide surgeons and pathologists with specific in-vivo and ex-vivo tumor margin, location, and orientation details. TrueMargin tools for open, minimally invasive, and robotic procedures enable communication and collaboration not seen before. Founded in 2022, the company is headquartered in Denver with significant operations in Tel Aviv and Haifa, Israel. Additional information is available at www.EmetSurgical.com or by emailing [email protected].
News published on and distributed by:
